ReviewCancer immunology, immunotherapy : CII2007
Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands.
Review in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Tumor infiltrating lymphocytes: The regulator of melanoma evolution.Oncology letters · 2019Review
- Article
- Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.Journal of cell communication and signaling · 2018Article
- Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.Molecular and cellular biochemistry · 2018Article
- Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.Human vaccines & immunotherapeutics · 2017Review
- Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy.Frontiers in immunology · 2015Review
- Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis.Stem cells and development · 2012Article
- Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Cancer immunology, immunotherapy : CII · 2011Review
- NK1.1 cells and CD8 T cells mediate the antitumor activity of Cl-IB-MECA in a mouse melanoma model.Neoplasia (New York, N.Y.) · 2011Article
- Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.Cancer immunology, immunotherapy : CII · 2009Review
- Betting on immunotherapy for melanoma.Current oncology reports · 2009Review
- Article
- Are cancer and ageing different sides of the same coin? Conference on Cancer and Ageing.EMBO reports · 2008Article
- Zinc, oxidative stress, genetic background and immunosenescence: implications for healthy ageing.Immunity & ageing : I & A · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, studies on the molecular and cellular mechanisms of immune responses against melanoma have contributed to a better understanding of how these tumours can be recognised by cytotoxic cells and the mechanisms they have developed to escape from innate and adaptive immunity. Lysis of melanoma cells by natural killer (NK) cells and cytolytic T cells is the result of a fine balance between signals transmitted by activating and inhibitory receptors. In addition to the T cell receptor, these were initially described as NK cell-associated receptors (NKRs) and were later also found on subsets of T lymphocytes, particularly effector-memory and terminally differentiated CD8 T cells. An increase of NKR(+)CD8(+) T cells has been found in melanoma patients, correlating with the expansion of differentiated effector CD8(+)CD28(null) CD27(null) T cells. NKRs can regulate the lysis of target cells expressing appropriate ligands. Activating receptors recognise ligands on tumours whereas inhibitory receptors are specific for MHC class I antigens and sense missing self. Altered expression of MHC class I antigens is frequently found on melanoma cells, preventing recognition by specific cytolytic T cells but favouring NK cell recognition. Changes in the expression of NKR-ligands in melanoma contribute in explaining the differences in the capacity of cytotoxic immune cells to control melanoma growth and dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.